Expression of ADAM10, 12, 17, and 28 Genes in Colorectal Cancer
International Journal of Molecular Sciences · 20.08.2026 · 27 (16) · 7441
DOI: 10.3390/ijms27167441 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2026. Verfasst von Agnieszka Kalita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition-Related Disease Prevention, Department of Metabolic Disease Prevention, Faculty of Public Health in Bytom, Medical University…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, ADAM Proteins, ADAM10 Protein, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.
Abstract (Originalsprache)
The role of adamalysins (ADAMs) has been widely described in many processes related to carcinogenesis, angiogenesis, inflammation, metastasis, and metabolic disorders. Despite numerous studies, their role in colorectal cancer (CRC) remains unclear. The aim of this study was to evaluate the expression of selected ADAM genes in colorectal cancer tissue and corresponding surgical margins. In addition, for a subgroup of patients, the expression of selected proteins from the ADAM family was assessed. The final study group consisted of 67 patients who underwent elective surgery for colorectal cancer. The relative expression of the ADAM10, 12, 17, and 28 genes was expressed as relative quantification (RQ) and determined by real-time quantitative PCR (RT-qPCR) in tumor tissue and surgical margins. In addition, for a subgroup of 45 patients, the expression of ADAM10, 12, and 17 proteins was assessed by ELISA. Associations between ADAM expression and clinicopathological parameters were analyzed statistically. ADAM12 gene expression was significantly higher in tumor than in margin tissue (median RQ: 0.995 vs. 0.251; p = 0.003), whereas ADAM28 RQ was significantly higher in the margin (median RQ: 0.400 vs. 0.204; p = 0.021). No significant differences were observed in the expression of the ADAM10, ADAM12, ADAM17, or ADAM28 genes based on tumor stage, sex, substance use, BMI, or age, except for nominally higher ADAM12 gene expression in patients over 65 years of age (p = 0.033). Among patients under 65 years of age with cardiovascular disease (CVD), ADAM28 RQ in tumor tissue was significantly higher than in those without CVD (p < 0.05). In obese patients with CVD, a markedly increased expression of ADAM28 in tumor tissue was observed, regardless of age (1.469 vs. 0.132; p < 0.005). Significant positive correlations were observed between the ADAM10 and ADAM17 RQ, and between the ADAM10 and ADAM28 RQ, in both tumor and marginal tissues (all adjusted p < 0.01). No significant correlations were found between gene expression and corresponding protein levels for ADAM10, ADAM12, or ADAM17. ADAM10, 12, 17, and 28 are poor biomarkers for colorectal cancer, but their significance may increase in patients with comorbid metabolic disorders. The lack of correlation between protein expression and gene expression suggests the contribution of post-transcriptional and post-translational regulatory mechanisms, which justifies further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition-Related Disease Prevention, Department of Metabolic Disease Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Department of Clinical Oncology, No. 4 Provincial Specialist Hospital, 41-902 Bytom, Poland.
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland.
- Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-514 Katowice, Poland.
ORCID-Profile: Agnieszka Kalita, Magdalena Sikora-Skrabaka, Karolina Gołąbek, Maria Dąbrowska, Joanna Katarzyna Strzelczyk, Dariusz Waniczek, Ewa Nowakowska-Zajdel
Förderung
- Medical University of Silesia
Zitieren
APA
Kalita, A., Sikora-Skrabaka, M., Gołąbek, K., Dąbrowska, M., Strzelczyk, J. K., Waniczek, D., Witkoś, A., & Nowakowska-Zajdel, E. (2026). Expression of ADAM10, 12, 17, and 28 Genes in Colorectal Cancer. International Journal of Molecular Sciences, 27(16), 7441. https://doi.org/10.3390/ijms27167441
Vancouver
Kalita A, Sikora-Skrabaka M, Gołąbek K, Dąbrowska M, Strzelczyk JK, Waniczek D, et al. Expression of ADAM10, 12, 17, and 28 Genes in Colorectal Cancer. International Journal of Molecular Sciences. 2026;27(16):7441. doi:10.3390/ijms27167441
BibTeX
@article{Kalita2026,
author = {Kalita, Agnieszka and Sikora-Skrabaka, Magdalena and Gołąbek, Karolina and Dąbrowska, Maria and Strzelczyk, Joanna Katarzyna and Waniczek, Dariusz and Witkoś, Andrzej and Nowakowska-Zajdel, Ewa},
title = {Expression of ADAM10, 12, 17, and 28 Genes in Colorectal Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7441},
doi = {10.3390/ijms27167441}
}
EUVIMED